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Abstract
Background: Metachromatic Leukodystrophy (MLD) is a rare, fatal demyelinating disorder with limited treatment
options. Published outcomes after hematopoietic stem cell transplantation (HSCT) are scant and mixed. We report
survival and function following HSCT for a large, single-center MLD cohort.
Methods: Transplant-related data, survival and serial measures (brain MRI, nerve conduction velocity (NCV), neurologic
and neuropsychology evaluations) were reviewed. When possible, parental interviews informed current neurologic
status, quality-of-life, and adaptive functioning. Gross motor and expressive functions for late-infantile (LI-MLD) and
juvenile (J-MLD) patients were described using previously reported, MLD-specific scales.
Results: Forty patients with confirmed MLD have undergone HSCT at our center. Twenty-one (53 %) survive at a
median 12 years post-HSCT. Most deaths (n = 17) were treatment-related; two died from disease progression. Survival
did not depend upon MLD subtype or symptom status at transplant. LI-MLD patients survive beyond reported life
expectancy in untreated disease.
Abnormal brain MRI and peripheral nerve conduction velocities (NCV) were common before HSCT. Following
transplant, fewer patients experienced MRI progression compared to NCV deterioration.
Sixteen LI-MLD and J-MLD survivors were evaluable for long-term gross motor and/or expressive language functioning
using existing MLD clinical scoring systems. While most J-MLD patients regressed, the aggregate cohort demonstrated
superior retention of function compared to published natural history.
Seventeen LI-MLD, J-MLD and adult subtype (A-MLD) survivors were evaluable for long-term adaptive functioning,
activities of daily living, and/or cognition. Relative cognitive sparing was observed despite overall global decline.
Five sibling pairs (one LI-MLD and four J-MLD), in which at least one underwent transplant in our cohort, were
evaluable. Within each familial dyad, survival or function was superior for the treated sibling, or if both siblings
were transplanted, for the pre-symptomatic sibling.
Conclusions: HSCT is a viable treatment option for MLD, but has significant limitations. Later-onset phenotypes may
benefit most from early, pre-symptomatic transplant. Until superior, novel treatment strategies are demonstrated, MLD
patients should be carefully considered for HSCT.
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Background
Metachromatic leukodystrophy (MLD) is a rare, fatal,
demyelinating lysosomal storage disease usually caused
by deficient arylsulfatase A (ARSA) enzyme activity. An
autosomal recessive disorder, MLD results from patho-
logic excess of cerebroside sulfatase (sulfatide), a major
lipid component of myelin [1]. Sulfatide accumulation
eventually leads to central and peripheral myelin de-
struction, producing the clinical and radiologic signs
characteristic of MLD [2]. If MLD is suspected, the diag-
nosis is typically made upon finding a combination of
low tissue ARSA activity and excessive urinary sulfatides.
Confirmation is often achieved by detecting causative
ARSA gene mutations.
Three distinct clinical subtypes of MLD are recognized
based on the age of disease manifestation: late-infantile
(LI-MLD, around 2 years of age), juvenile (J-MLD, ages
3-16 years), and adult (A-MLD, ages >16 years) [3]
While MRI findings are generally consistent across phe-
notypes, the neurobehavioral changes vary by subtype
[4]. LI-MLD and occasionally J-MLD can present with
rapid global neurologic regression over months and result
in early death without treatment. Neurologic findings in
these earlier-onset phenotypes are primarily motor related,
including weakness, gait abnormalities, quadriparesis, dys-
arthria, hearing difficulties, vision impairment, and incon-
tinence [5]. In contrast, patients with later onset of disease
may present with a neuropsychiatric or cognitive pro-
drome, including frontal lobe dysregulation, which can be
followed by gradual but frank neurologic decline [6].
Treatment options for MLD remain limited.
Hematopoietic stem cell transplantation (HSCT) has
been used for decades on the basis of providing meta-
bolic cross-correction, in which functional ARSA from
donor-derived cells promotes sulfatide degradation.
However, reports of transplant outcomes in the med-
ical literature are relatively few and conclusions are
mixed [7–17].
Therefore, we performed a single-center, retrospect-
ive review of long-term outcomes following HSCT for
patients diagnosed with MLD. We aimed to describe
survival, transplant-related, neuroradiographic, neuro-
physiologic, gross motor, expressive language, neuro-
cognitive and quality-of-life outcomes. This report,
believed to be the largest known of its kind, aims to
more clearly illuminate the longitudinal functional and
clinical outcomes after HSCT.
Methods
Cohort identification, patient-related data and
transplant-related measures
All patients undergoing HSCT for the diagnosis of MLD
were identified from the prospectively maintained Univer-
sity of Minnesota Blood and Marrow Transplant Database
(BMT Database). Those whose MLD diagnosis could be
retrospectively confirmed were included for this analysis.
MLD diagnosis was considered confirmed if (1) the pa-
tient had low ARSA with elevated urine sulfatides (n = 39);
or (2) the patient had low ARSA, radiographic and clinical
evidence of leukodystrophy and an affected sibling with
low ARSA and elevated urine sulfatides (n = 1). For
each patient, data were collected from the BMT Data-
base, medical record review, and/or parental telephone
surveys (approved by the Institutional Review Board
[IRB] and following the provision of informed consent).
All efforts were made to extract the following information
per patient: age at clinical MLD onset, reason for diagno-
sis, family history of MLD, age at HSCT, transplant condi-
tioning intensity, allograft source, donor-recipient human
leukocyte antigen (HLA) compatibility, occurrence and
time to neutrophil and platelet recovery, occurrence
and severity of acute and chronic graft-versus-host
disease (aGvHD, cGvHD) [18, 19], most recent post-
transplant donor hematopoietic engraftment, most recent
leukocyte ARSA activity, survival status, cause of death
(where applicable), and time to most recent follow-up or
death.
Though MLD diagnosis was assigned to each patient
prior to transplant by the evaluating neurologist and
BMT physician, available records were also reviewed
for confirmation of diagnosis. Baseline (pre-transplant)
leukocyte ARSA activity and urine sulfatide excretion
were noted to be primary source (laboratory report
available for review) or secondary source (laboratory result
referenced in the medical record). Medical histories and
examinations were reviewed for dermatologic or musculo-
skeletal findings consistent with multiple sulfatase defi-
ciency. MLD subtype assignment was retrospectively
assigned by age when disease became clinically evident in
a patient or sibling proband(s) according to the medical
record. Subtype assignment followed criteria used in
the largest published natural history study to date: LI-
MLD disease, < 30 months; J-MLD disease, 30 months
to 15 years; A-MLD disease, ≥ 16 years [20]. Patients
were defined as symptomatic if they demonstrated any
clinical evidence of MLD at the time of transplant.
All patients were treated in accordance with the
Declaration of Helsinki on protocols approved by the
University of Minnesota IRB. Patients or guardians pro-
vided informed consent for treatment and publication of
outcome data. Conditioning regimens and hematopoietic
stem cell allografts were selected according to institutional
algorithms at the time of transplantation. HLA typing of
donors and recipients was by allele- or antigen-based
methods, depending upon institutional guidelines at the
time. All sibling donors were screened for leukocyte
ARSA activity and determined for carrier status by the
treating BMT physician. Neutrophil recovery was defined
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as the first of 3 consecutive days with a peripheral blood
neutrophil count ≥ 500/μL. Platelet recovery was defined
as the first of 7 consecutive days with a transfusion-
independent peripheral platelet count ≥ 20 x 103/μL. Most
recent donor hematopoietic engraftment was determined
according to existing institutional guidelines on either
marrow-aspirated nucleated cells, unfractionated per-
ipheral blood leukocytes, or myeloid-enriched periph-
eral blood leukocytes. Most recent leukocyte ARSA
activity was determined by clinical laboratory measure-
ment. Each patient underwent GvHD prophylaxis accord-
ing to existing protocol. Infectious disease prophylaxis,
growth factor administration, and blood product support
were per University of Minnesota BMT Program standard
of care guidelines.
Gross motor and expressive language function evaluation
Longitudinal gross motor and expressive language func-
tioning over time for LI-MLD and J-MLD long-term
survivors were assessed with the Gross Motor Function
Classification for MLD (GMFC-MLD) and Expressive
Language Function Classification for MLD (ELFC-MLD)
scales, as previously reported (Fig. 1) [20–22]. The age
at entry into a given level on both scales was tracked for
each patient. When possible, current and retrospective
GMFC-MLD and ELFC-MLD data were obtained via
parental telephone survey using the methodology de-
scribed by Kehrer [20]; otherwise, most recent scores
and ages at entry into levels were constructed through
review of detailed clinical neurology assessments in the
medical record.
Brain magnetic resonance imaging and peripheral nerve
conduction velocity studies
Clinical brain MRI reports at pre-HSCT and post-HSCT
time points were reviewed as available for all MLD sub-
types. Each report was characterized according to the
presence or absence of pathologic white matter findings
and whether changes relative to the previous scan (worse,
stable, or better) were noted by the interpreting neurora-
diologist. The presence or absence of atrophy was not
considered when assessing serial MRI reports, as incon-
sistencies in reporting volume loss were noted upon re-
view of records. Similarly, clinical nerve conduction
velocity (NCV) reports from pre-HSCT and post-HSCT
time points were reviewed as available for all cohort
members. Each report was assessed for the presence or
absence of abnormalities and whether general changes
relative to the previous study (worse, stable, or better)
were noted by the interpreting neurologist.
Neuropsychologic, adaptive behavior functioning and
quality-of-life assessments
Neuropsychology records of all long-term cohort survi-
vors were reviewed for assessment of cognition and adap-
tive behavior functioning at all available pre-HSCT and
post-HSCT time points. Cognition was trended longitu-
dinally with standardized Verbal Intelligence Quotient
(VIQ) scores by Wechsler-series assessments [23]. In rare
instances when VIQ data was not available at a time point,
Wechsler Full-Scale scores (FSIQ, n = 1) or equivalent do-
main scores on the Stanford-Binet (n = 1) or Bayley Scales
of Infant Development (n = 2) tools were used [24, 25].
Fig. 1 Gross Motor Function Classification (GMFC-MLD) and Expressive Language Function Classification (ELFC-MLD) scales in metachromatic
leukodystrophy. The previously reported scales describe both gross motor and expressive language deterioration over time for late-infantile and
juvenile subtypes of MLD. Long-term survivors in the HSCT cohort were evaluated for scores at most recent follow-up and age-to-entry into various
levels over time
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Similarly, age equivalent composite adaptive behavior
function as assessed by the Vineland Adaptive Behavior
Scales (VABS) was trended over time for all long-term
survivors [26]. When possible, current VABS scores
were generated for this analysis via parental telephone
survey (n = 14).
We further used recent parental surveys to assess sev-
eral other outcomes and attitudes following HSCT for
all subtypes of MLD. First, long-term survivor quality-
of-life was measured by the Cornell-Brown Scale (CBS)
[27]. Next, the age at loss of independent performance
of common activities of daily living (ADLs) was deter-
mined. Finally, parental attitude regarding satisfaction
with having chosen HSCT for their child with MLD
was assessed.
Comparison of transplant outcomes and natural history
for MLD sibling pairs
When available, long-term survival and functional out-
come data (GMFC-MLD, ELFC-MLD, VABS and ADL)
between sibling pairs with MLD were evaluated for de-
scriptive purposes. For some pairs, only one sibling under-
went HSCT at our center. Data for non-transplanted
siblings (n = 3), or siblings transplanted at another center
(n = 1) were obtained by parental telephone survey.
Statistical analyses
Statistical analyses were descriptive and used standard
summary measures such as frequencies, medians, and
interquartile ranges. Overall survival from time of HSCT
was calculated using the Kaplan-Meier method [28]. The
cumulative incidence function with competing risks was
used to estimate transplant-related mortality (TRM; com-
peting risk = death from MLD progression), along with
neutrophil recovery, platelet recovery, and GvHD (com-
peting risk = death) [29].
Results
Cohort characteristics, survival and transplant-related
outcomes
Forty-three patients underwent HSCT for a reported
diagnosis of MLD at the University of Minnesota with
transplant dates spanning June 1984 to April 2013
(Table 1). Forty patients (93 %) in whom diagnosis could
be confirmed were ultimately considered for analysis.
Twelve patients (30 %) were male. Four patients (10 %)
had LI-MLD, 27 (67 %) had J-MLD, and 9 (23 %) had A-
MLD. Five patients (12 %) underwent reduced-intensity
conditioning (RIC) using melphalan, clofarabine, low-
dose total-body irradiation (TBI) and alemtuzumab. The
remaining 35 (88 %) received myeloablative condition-
ing that was either busulfan/cyclophosphamide (Bu/Cy)
or cyclophosphamide/TBI (Cy/TBI)-based. Eleven pa-
tients (27 %) received related-donor marrow, 14 (35 %)
received unrelated-donor marrow, and 15 (38 %) re-
ceived umbilical cord blood (UCB) transplants. In four
patients (10 %), the sibling donor was considered a car-
rier due to low leukocyte ARSA activity, though full
cataloging of parental and sibling ARSA activities and
genotyping (for the exclusion of possible pseudodeficiency
allele carriage to explain ARSA hypo-activity) was not
performed [30]. Three patients underwent a second
transplantation due to autologous hematopoietic recov-
ery: Patient ID9 at 4 months after first HSCT, ID5 at
18 months, and ID11 at 6 months.
Thirty-nine patients (98 %) had primary and/or sec-
ondary source data documenting baseline low leukocyte
ARSA activity and elevated urine sulfatide excretion for
confirmation of MLD diagnosis (Table 2). No patient
had records of exam findings consistent with multiple
sulfatase deficiency. In one patient with low baseline
ARSA activity and white matter abnormalities evident on
brain MRI, low ARSA and elevated urine sulfatide were
documented in an affected sibling. In three separate pa-
tients who underwent HSCT for MLD, all with abnormal
NCV studies and white matter disease on brain MRI, no
urine sulfatide data was found. These patients were ex-
cluded from analysis due to the absence of confirmatory
testing for MLD. For these 3 patients, neither ARSA
molecular data nor nervous tissue biopsy data was
available for genotypic or histopathologic confirmation
of diagnosis.
Twenty-one patients (53 %) are alive at a median post-
transplant follow-up of 10 years. For the entire cohort,
the Kaplan-Meier (KM) estimate of survival at 5 years is
59 % (95 % confidence interval [CI95], 42 % - 73 %;
Fig. 2). For each MLD subtype, the KM estimate of sur-
vival at 5 years was as follows: LI-MLD, 50 % (CI95, 6 %
- 84 %); J-MLD, 59 % (CI95, 38 % - 75 %); A-MLD, 67 %
(CI95, 28 % - 88 %; Fig. 2). For the entire cohort, sur-
vival was independent of the conditioning regimen,
MLD subtype, and the presence of symptoms at the time
of transplantation. A trend toward inferior survival was
noted for recipients of unrelated marrow allografts, as
compared to those who underwent related-donor or
UCB transplantation.
The cumulative incidence of neutrophil recovery for the
entire cohort was 95 % (CI95, 84 % - 99 %) at a median day
+16 (CI95, days 12 - 17). The cumulative incidence of
platelet recovery was 80 % (CI95, 58 % - 96 %) at a median
day +42 (CI95, days 33 - 53). The cumulative incidence of
Grade II-IV aGvHD was 44 % (CI95, 26 % - 62 %) and
Grade III-IV aGvHD was 16 % (CI95, 4 % - 29 %). The
cumulative incidence of any cGvHD was 32 % (CI95,
14 % - 50 %). The cumulative incidence of TRM by day
+180 was 23 % (CI95, 12 % - 36 %). Five patients expe-
rienced primary autologous hematopoietic recovery, 2
of these (40 %) following RIC.
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Table 1 Patient demographics, transplant-related and survival characteristics
Cohort ID Gender Time from symptom





















1 M X 0,4 1996 MA (Bu/Cy) cRD 6/6 100 (0,4) — 0,3a VOD
2 M X 0,5 2004 MA (Bu/Cy) UCB 5/6 100 (2,11) 100 (2,10) 4,10
3 F X 0,8 1995 MA (Bu/Cy) cRD 6/6 100 (8,4) 60 (6,10) 19,6
6 F 0,6 2,10 1995 MA (Bu/Cy) URD 5/6 100 (1,6) 100 (1,0) 1,6a unknown
Juvenile
4 F 1,10 4,10 1984 MA (Bu/Cy) RD 6/6 100 (15,1) 100 (25,2) 30,6
9 F 1,2 4,2b 2001 MA (Cy/TBI) URD 6/6 100 (4,9) 100 (3,5) 13,3
5 F X 1,3b 1994 MA (Bu/Cy) URD 6/6 100 (0,3) — 2,2a cGvHD
7 F X 2,8 1994 MA (Bu/Cy) URD 6/6 100 (0,2) — 0,3a VOD
8 F X 3,5 1994 MA (Bu/Cy) URD 6/6 97 (6.5) 100 (6,5) 8,2
22 F X 11,1 2004 MA (Bu/Cy) dUCB 4/6 + 4/6 100 (3,2) 100 (0,6) 10,7
10 F 0,5 5,8 1996 MA (Cy/TBI) URD 6/6 60 (11,3) 38 (11,3) 18,7
11 F 0,10 5,10b 1998 MA (Cy/TBI) cRD 5/6 100 (2,6) 25 (2,6) 7,2a MLD
12 F 1,1 5,11 2008 RIC UCB 6/6 2 (0,1) 8 (0,1) 3,1a MLD
13 F 0,11 6,4 1989 MA (Bu/Cy) RD 6/6 — 73 (0,1) 0,2a MSOF
14 F 2,3 6,3 2002 MA (Bu/Cy) UCB 4/6 100 (2,0) 100 (2,0) 2,0
15 F 0,0 6,7 1997 MA (Bu/Cy) URD 6/6 100 (1,7) 100 (1,7) 7,3
16 F 3,6 7,6 1999 MA (Cy/TBI) URD 5/6 67 (3,5) 59 (1,9) 15,7
17 M 2,8 7,8 2003 MA (Bu/Cy) UCB 5/6 100 (0,6) 100 (0,6) 11,9
18 M 0,10 8,4 1997 MA (Bu/Cy) URD 6/6 100 (0,7) 100 (0,6) 0,7a Sepsis
19 M 0,9 8,7 2002 MA (Bu/Cy) UCB 5/6 100 (0,5) 100 (0,5) 10,6a cGvHD
20 F 2,4 11,1 2005 MA (Bu/Cy) dUCB 4/6 + 4/6 100 (0,3) 100 (0,3) 0,3a Sepsis
21 F 2,0 10,4 1995 MA (Bu/Cy) RD 6/6 100 (0,1) — 0,2a aGvHD
23 M 2,7 11,6 1991 MA (Bu/Cy) URD 6/6 — 50 (0,7) 0,7a Sepsis
24 F 1,5 14,8 1989 MA (Bu/Cy) RD 6/6 100 (16,4) 100 (16,4) 16,4
25 F 1,7 16,4 2004 MA (Bu/Cy) dUCB 6/6 + 6/6 100 (0,4) 100 (0,2) 0,5a TTP
26 F 1,10 16,2 1994 MA (Bu/Cy) cRD 6/6 100 (9,5) 100 (11,0) 12,6
27 F 5,1 16,1 2004 MA (Bu/Cy) UCB 4/6 100 (3,2) 100 (3,2) 10,7














Table 1 Patient demographics, transplant-related and survival characteristics (Continued)
30 M 10,5 20,5 2000 MA (Cy/TBI) URD 5/6 100 (0,2) 100 (0,2) 0,6a Sepsis
32 F 16,3 27,7 1996 MA (Cy/TBI) RD 6/6 44 (2,0) 32 (2,0) 18,2
43 M 5,8 19,8 2013 RIC RD 6/6 100 (1,1) 100 (1,1) 1,6
Adult
42 F X 20,1 1995 MA (Bu/Cy) URD 5/6 100 (0,1) — 0,1a VOD
31 M 9,1 27,1 2003 MA (Bu/Cy) UCB 4/6 100 (0,2) — 0,3a Graft
Failure
33 F 10,10 29,10 1999 MA (Cy/TBI) URD 6/6 100 (3,0) 100 (3,0) 10,0
34 M 3,7 33,7 2000 MA (Cy/TBI) URD 5/6 100 (1,5) 64 (0,1) 10,0
36 F 5,4 38,1 1999 MA (Cy/TBI) RD 6/6 35 (2,3) 76 (1,0) 1,1
38 F 0,11 40,7 2001 MA (Cy/TBI) UCB 5/6 100 (0,3) 100 (0,3) 0,4a Sepsis
39 M 5,5 42,5 2007 RIC dUCB 5/6 + 5/6 100 (0,6) 100 (1,3) 7,6
40 F 3,5 42,6 2007 RIC dUCB 5/6 + 6/6 80 (2,9) 100 (1,2) 6,5a unknown
41 F 3,2 44,2 2007 RIC dUCB 4/6 + 5/6 0 (1,1) 50 (0,2) 1,1
y Year, m Month, X Asymptomatic, MA Myeloablative, Bu Busulfan, Cy Cyclophosphamide, TBI Total-body irradiation, RIC Reduced-intensity conditioning, RD Related marrow donor (sibling), URD Unrelated marrow
donor, UCB Umbilical cord blood, d Double cord, c MLD-carrier marrow donor, a Deceased, VOD Hepatic
veno-occlusive disease, MSOF Multi-system organ failure, aGVHD Acute graft-vs-host disease, cGvHD Chronic graft-vs-host disease, b Age denoted is time of first transplant, c Most recent time point available, expressed




































1 0,1 Fam Lowa Yes (3.4) No Data Yes Sibling proband symptomatic
before 2 years old
2 0,1 Fam 3.3 Yesa No Yes Yes Sibling proband symptomatic
before 2 years old
3 0,4 Fam 3.0 Yes (4.9) Yes Yes Yes Sibling proband symptomatic
before 2 years old
6 1,3 Fam/SS Lowa Yes (4.8) Yes Yes Yes Yes Two sibling probands
symptomatic at 2 years old
Juvenile
4 0,5 Fam 9.2 Yes (2.5) No Data Yes Yes Yes
9 3,11 SS 3.9 Yes (Excessiveb) Yes Yes Yes Yes
5 0,10 Fam Lowa,c Yes (5.2) No Data Yes Yes Sibling proband symptomatic at
3 years old
7 2,2 Fam Lowa Yes (10.3) Yes Yes Sibling proband symptomatic
before 8 years old
8 3,1 Fam 2.0 Yes (10.9) Yes Yes Yes Sibling proband symptomatic
before 5 years old
22 10,10 Fam 8.6 Yes (Excessiveb) Yes Yes Yes Yes Sibling proband symptomatic at
11 years old
10 5,2 Fam/SS 5.5 Yes (6.7) Yes Yes Yes Yes
11 5,7 SS 3.4 Yes (6.4) Yes Yes
12 5,8 SS 8.8 Yes (5.9) Yes No Data
13 6,0 SS 9.3 Yes (3.6) Yes Yes
14 6,0 SS 8.9 Yes (17.9) Yes Yes
15 6,4 Fam/SS 8.3 Yes (Excessiveb) No Data Yes
16 7,2 SS 2.7 Yes (7.9) Yes Yes Yes Yes
17 7,6 SS 6.7 Yes (9.3) Yes Yes Yes
18 8,3 Fam/SS 11.2 Yes (Excessiveb) No Data Yes
19 8,5 SS 15.5 Yes (5.4) Yes Yes Yes
20 9,9 Fam/SS 1.9 Yes (3.0) Yes Yes
21 10,3 Fam/SS 43.2 Yes (1.1) Yes Yes














Table 2 MLD-related characteristics (Continued)
24 14,2 Fam/SS 5.2 Yes (3.1) Yes Yes Yes
25 15,6 SS 3.6 Yes (0.7) Yes Yes
26 15,9 SS 4 % normald Yes (2.4) Yes Yes Yes Yes
27 15,10 SS 6.8 Yes (Excessiveb) Yes Yes Yes Yes
28 15,11 SS 7.7 Yes (3.2) Yes Yes
30 19,8 SS 6.0 Yes (Excessiveb) Yes Yes
32 26,4 SS 35.1 Yes (Excessiveb) Yes Yes Yes
43 19,2 SS 4.1 Yes (Excessiveb) Yes Yes
Adult
42 20,1 Fam 7.9 Yes (1.3) Yes Yes Two older siblings reportedly
with MLD
31 26,0 SS 3.7 Yes (3.8) Yes No
33 28,10 SS 8.7 Yes (3.5) Yes Yes Yes
34 32,0 Fam/SS 10.3a No Data Yes No Sibling of Patient ID 33
36 35,9 SS 3.5a Yesa Yes No Yes Yes
38 40,0 Fam/SS 5.9 Yes (8.2) Yes Yes
39 42,0 SS 10 % normald Yesa Yes Yes Yes Yes
40 42,1 Fam/SS Lowa Yes (6.6) Yes Yes
41 43,10 SS 21.8 Yes (6.6) Yes Yes Yes Yes
y Year, m Month, ! Denotes if patient included for long-term adaptive behavior functioning or cognition in this analysis, Fam Family history, SS Signs or symptoms of MLD, a Primary laboratory result not found; results
as stated in medical record, b Primary laboratory result reported qualitatively only, c Additional primary result of 16.0 nmol/hr/mg following HSCT with donor hematopoietic engraftment of 25 %, d Primary laboratory














Gross motor and expressive language function outcomes
Sixteen long-term survivors with either LI-MLD (n = 2) or
J-MLD (n = 14) were evaluable for longitudinal gross
motor and/or expressive language functioning by the
GMFC-MLD and ELFC-MLD scales, respectively (Figs. 3
and 4). The median post-HSCT time to most recent
evaluation was 12 years, 5 months, while the median age
to most recent evaluation was 21 years, 6 months. For 11
of these patients, performance on the scales was deter-
mined by recent telephone interview. For the remaining 5
patients, scores were constructed using clinical neurology
assessments in the medical record.
Brain MRI and peripheral NCV outcomes
Thirty-five patients (88 %) had at least one pre-HSCT
brain MRI report available for review (Fig. 5). For 34 of
these patients (97 %), baseline abnormal white matter
was observed. Twenty-three patients (66 %) had at least
one post-HSCT study beyond day +60 with a median
time to last follow up of 23 months (Interquartile
Range (IQR), 9 months - 57 months; range, 2 months -
306 months). Of those patients, only 7 (31 %) had post-
HSCT reports describing worsening demyelination,
while the majority (n = 12, 52 %) demonstrated stable
scans. Four patients (17 %; Patients ID2, ID3, ID24, and
ID33) had recognizable improvement in white matter
disease over time.
Thirty-nine patients (98 %) had at least one pre-HSCT
NCV report available for review (Fig. 5). In 36 (92 %) of
these patients, neuropathy was present before transplant.
Twenty-one patients (54 %) had at least one post-HSCT
study beyond day +60, with a median time to last follow-
up of 24 months (IQR, 12 months – 78 months; range,
3 months – 306 months). Of this group with long-term
Fig. 2 Kaplan-Meier survival estimates following HSCT for MLD. a Probability of survival at 5 years following HSCT for the entire cohort (n = 40).
b Probability of survival at 5 years following HSCT for individual MLD subtypes: LI-MLD (n = 4); J-MLD (n = 27), and A-MLD (n = 9)
Fig. 3 Age to entry into GMFC-MLD levels for LI-MLD and J-MLD patients in the HSCT cohort. Numbers preceding each line refer to the Patient
ID (see Tables 1 and 2). Circles represent time at entry into a respective level. Each line ends at most recent follow-up. Some patients had evaluable
gross motor function data prior to HSCT. See Fig. 1 for GMFC-MLD level definitions. Patients were labeled symptomatic at the time of HSCT if they
exhibited any clinical manifestation of MLD
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post-transplant NCV follow-up, 16 (76 %) demonstrated
worsening neuropathy.
Neuropsychologic, adaptive behavior functioning and
quality-of-life outcomes
Seventeen patients were evaluable for cognitive and/or
adaptive behavior functioning over time. VABS data gen-
erally reflected significant decline in adaptive behaviors
in the immediate months to years after HSCT for all
subtypes (Fig. 6). Though all 3 evaluable LI-MLD pa-
tients demonstrated normal-for-age adaptive behavior
at baseline, the lone patient with extensive follow-up
showed significant eventual functional decline. The ma-
jority of evaluable J-MLD and A-MLD patients demon-
strated adaptive behavior functional impairment at
baseline, and most continued to show decline. A simi-
lar trend of post-transplant decline, though perhaps
slightly more blunted, was seen for VIQ across all sub-
types (Fig. 7). Numerical scores were mostly greater
than zero across all subsets on the CBS for 12 evaluable
survivors, suggesting a favorable quality-of-life (Table 3).
Times-to-loss of common ADLs for these same pa-
tients are shown in Table 4. When asked, “Are you sat-
isfied with your decision to have your child undergo
BMT for MLD?” all 11 parental respondents answered,
“Yes” at a median 13 years, 3 months post-HSCT. One
surveyed parent declined to respond.
Outcome comparisons between MLD sibling pairs
Five MLD sibling pairs were evaluable for some or all of
the following outcomes: death from disease progression,
gross motor function, expressive language function,
adaptive functioning, and independent performance of
ADLs (Table 5) Three familial pairs (ID3/sib3, LI-MLD;
ID4/sib4, J-MLD; and ID10/sib10, J-MLD) consisted of
one transplanted (within our cohort) and one non-
transplanted sibling. One pair (ID22/ID27, J-MLD) con-
sisted of two sisters both transplanted within our cohort
(one symptomatic and the other pre-symptomatic at
HSCT). The final pair (ID17/sib17, J-MLD) consisted of
two siblings both transplanted, one within our cohort
(symptomatic at HSCT) and the other at another center
(pre-symptomatic at HSCT).
Discussion
This retrospective, single-center review of 40 patients
undergoing allogeneic HSCT for MLD is the largest to
date. In this study, we aimed to characterize survival and
long-term functional outcomes associated with trans-
plantation. The estimated survival at 5 years post-HSCT
was 59 %. Survival did not depend on the MLD subtype
classification of the patient, nor did it depend upon the
presence of symptoms at the time of transplant. In gen-
eral, previous studies and case reports have documented
improved survival outcomes for transplants performed
pre-symptomatically or in those with older age at disease
onset [7–9, 11, 12]. However, our data suggest that
allograft source may play a more significant role. Not
surprisingly, a trend towards improved survival was seen
for those who received HLA-matched sibling marrow
grafts. For patients receiving unrelated donor grafts, sur-
vival following UCB transplantation appeared favorable
as has been previously reported [7]. Most deaths in our
cohort occurred from treatment-related complications
within the first year of transplant and comparatively few
patients died due to progressive MLD. It is difficult to
know whether the relatively high incidence of TRM at
6 months (23 %) is dependent to any degree upon the
Fig. 4 Age to entry into ELFC-MLD levels for LI-MLD and J-MLD patients in the HSCT cohort. Numbers preceding each line refer to the Patient ID
(see Tables 1 and 2). Circles represent time at entry into a respective level. Each line ends at most recent follow-up. Some patients had evaluable
expressive language function data prior to HSCT. See Fig. 1 for ELFC-MLD level definitions. Patients were labeled symptomatic at the time of HSCT
if they exhibited any clinical manifestation of MLD
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diagnosis of MLD itself. Importantly, a significant fraction
of the cohort was treated in an era when HSCT was riskier,
regardless of the underlying disease necessitating trans-
plant. With advances in donor-recipient HLA typing and
matching, pathogen detection, antimicrobial therapies, bu-
sulfan targeting and allograft availability, it is likely that a
similar cohort transplanted in the current era would dem-
onstrate less TRM.
Fig. 5 Brain MRI and NCV trends over time. All available clinical reports of brain MRI and peripheral nerve conduction velocity studies for the
cohort were reviewed. Each MRI time-point was evaluated for change in white matter disease from the previous study as classified by the
interpreting neuroradiologist. Each NCV time-point was evaluated for change in function from the previous study as classified by the interpreting
neurologist. Each line represents a unique patient, while each circle represents an assessment. The dashed vertical line at time 0 reflects the time
of transplant. Negative time points denote pre-HSCT studies. Red, yellow and green circles and preceding line segments indicate MRI or NCV
studies that were worse than, the same as, or better than the previous assessment, respectively. Of evaluable patients at pre-transplant baseline,
97 % had an abnormal MRI while 92 % demonstrated peripheral neuropathy
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Five patients underwent RIC transplantation according
to existing institutional protocols available at the time of
treatment. While no TRM was observed for these 5 pa-
tients, 2 (40 %) experienced autologous hematopoietic
recovery. Even for those who demonstrated donor en-
graftment, an essential question that cannot be answered
in this analysis due to insufficient numbers of evaluable
long-term survivors is whether the agents and doses
employed in transplant conditioning might impact long-
term neurologic outcomes. While a rational argument
can be made for the use of CNS-sparing regimens for
transplantation of neuropathic metabolic disorders, recent
pre-clinical data suggest that HSCT conditioning using
CNS penetrating agents, in particular high-dose busulfan,
improves donor-derived microglial engraftment which
may then be essential for metabolic cross-correction
within the CNS [31, 32]. It is perhaps noteworthy that all
fatal veno-occlusive disease of the liver (n = 3) in our
Fig. 6 Vineland Adaptive Behavior Scale (VABS) scores over time. Serial trends in composite VABS over years for all long-term survivors after HSCT
are shown by MLD subtype. A triangle represents a pre-HSCT score while a circle represents a post-HSCT score. Green indicates patients
pre-symptomatic at the time of HSCT. Red indicates patients symptomatic at the time of HSCT. Calendar and functional age equivalence in
years is shown by the solid diagonal line, with the dashed lines representing two standard deviations from the mean
Boucher et al. Orphanet Journal of Rare Diseases  (2015) 10:94 Page 12 of 19
cohort occurred following busulfan-based conditioning, as
MLD can be associated with abnormalities of the biliary
system [3]. However, this complication may be expected
to be less frequent in the era of therapeutic busulfan
monitoring, as data from a more modern MLD trans-
plant cohort is notable for an absence of morbidity
from veno-occlusive disease [7].
It is difficult to assess whether transplantation provided a
survival advantage compared to natural history for patients
within our cohort who did not die from transplant-related
causes. Perhaps the largest analysis for untreated MLD sur-
vival is provided by a recent literature meta-analysis of 98
LI-MLD, 78 J-MLD, and 127 A-MLD patients [33]. In that
report which recognized variability in the “definition” of
disease subtypes, the estimated J-MLD survival probability
was 50 % at approximately 10 years following MLD symp-
tom onset. Among 16 J-MLD patients in our cohort who
did not die from transplant-related causes, 2 have died from
progressive MLD at 8 years and 5 years following initial dis-
ease onset. Fourteen J-MLD patients survive at a median
most recent follow-up of 14.5 years following first symp-
toms (or from when symptoms would be anticipated based
on proband sibling history). Comparison of LI-MLD and
A-MLD is difficult owing to relatively small numbers within
our cohort.
Long-term neurologic function remains a highly rele-
vant outcome following any therapeutic intervention for
MLD. Despite this, relatively few robust, prospective,
longitudinal natural history descriptions exist for MLD.
Biffi et al provided perhaps the most thorough such ana-
lysis with their assessment of 26 primarily LI-MLD and
J-MLD patients in which they catalogued performance
on detailed motor and neuropsychological scales over time
[34]. The retrospective nature of our analysis did not allow
for such high-resolution longitudinal assessments of our co-
hort. However, investigators with the German LEUKONET
group have recently developed and applied simpler scales
to describe the decline of gross motor and expressive
language function in large, untreated LI-MLD and J-MLD
cohorts [20–22]. Importantly, their GMFC-MLD and
ELFC-MLD tools were designed for either prospective or
retrospective assessment of an individual patient over time.
For this analysis, we used detailed longitudinal clinical
neurology notes or, when possible, recent parental tele-
phone interviews to assess individual performance on the
GMFC-MLD and ELFC-MLD scales for long-term survi-
vors. Only two surviving patients in our transplanted
MLD cohort fit late-infantile classification as employed by
the LEUKONET natural history study, One of these LI-
MLD patients (ID3), pre-symptomatic at transplant,
showed rapid decline similar to natural history expecta-
tions as described by the LEUKONET group. The other
(ID2), also pre-symptomatic at transplant, demonstrated
more protracted motor decline post-HSCT compared to
that reported in the large LEUKONET LI-MLD cohort
(Fig. 3) [20]. Similarly, Brazilian investigators documented
a relatively large LI-MLD natural history cohort, but in-
cluded all children who became symptomatic before the
age of 48 months. When extrapolated to the GMFC-
MLD scale, reported mean ages at entry to motor levels
3, 5 and 6 were 26, 27 and 25.6 months, respectively,
Fig. 7 Intelligent Quotient (IQ) Trends over time for MLD subtypes.
Trends in IQ scores over time for all long-term survivors after HSCT
are shown by MLD subtype. A triangle represents a pre-HSCT score
while a circle represents a post-HSCT score. Green indicates patients
who were pre-symptomatic at the time of HSCT. Red indicates
patients who were symptomatic at the time of HSCT. All but two of
the scores shown (both for one J-MLD patient, indicated by asterisk)
denote Verbal IQ. The solid line represents a mean IQ score of 100
and the dashed lines are two standard deviations from the mean
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for their untreated “late-infantile” patients [17]. In con-
trast, when considering all four long-term survivors in
our transplanted cohort who met this definition for
“late-infantile” MLD applied to the Brazilian cohort
(ID2, 3, 4 and 9) the ages to entry into the same motor
levels were 70, 86, and 137 months, respectively. These
findings suggest that HSCT may attenuate the steep motor
decline for some LI-MLD patients, even though all such
transplanted patients in our cohort ultimately experienced
severe motor dysfunction.
Only one long-term surviving LI-MLD patient in our
cohort (ID3) was evaluable for expressive language func-
tion compared to existing natural history description by
LEUKONET. She showed a similar trend compared to
untreated patients with perhaps modest prolongation of
expressive language function [22]. When extrapolated to
the ELFC-MLD tool, the large Brazilian “late-infantile”
cohort appeared to enter level 4 at a mean age of
25.4 months [17]. For three evaluable long-term survi-
vors in our transplanted cohort meeting the same defin-
ition of “late-infantile” applied in the Brazilian analysis,
the mean age at entry into level 4 was 74.5 months (with
one patient, ID4, still expressing single word ideas at
34 years of age). Again, these findings suggest that
HSCT might modestly blunt the rapid expressive language
deterioration in untreated very early-onset MLD, even as
all such transplanted patients in our cohort ultimately ex-
perienced severe expressive language dysfunction.


















3 LI 19,11 8,2 6 0 1 -1 -2 4
4 J 34,11 28,2 8 0 4 0 5 17
9 J 17,4 10,5 7 0 -1 -3 2 5
10 J 24,1 12,10 7 3 -1 0 0 9
16 J 22,11 12,3 5 6 -2 -1 1 9
17 J 19,4 5,3 5 0 -2 0 3 6
19 J 19,0 10,5 -5 1 -5 -2 -2 -13
22 J 21,7 9,0 3 3 3 2 -2 9
27 J 26,7 9,0 7 2 1 0 3 13
32 J 45,6 14,10 8 0 5 4 6 23
43 J 21,2 1,6 4 5 6 -1 0 14
39 A 49,9 5,7 0 2 0 0 3 5
Total and sub-domain scores for evaluable long-term survivors using the CBS. More negative (less than zero) scores indicate decreasing quality-of-life; more
positive (greater than zero) scores indicate increasing quality-of-life. LI Late-Infantile, J Juvenile, A Adult, a Age when survey administered, y Year, m Month





















3 LI 19,11 8,2 — — — — — — — —
4 J 34,11 28,2 — 13,0 — — — 21,0 26,0 —
9 J 17,4 10,5 — 5,0 — — 4,0 13,0 — —
10 J 24,1 12,10 5,10 6,6 — 6,6 7,0 + — —
16 J 22,11 12,3 8,4 10,11 — 8,0 8,0 7,0 — —
17 J 19,4 5,3 9,0 9,0 — 6,0 8,0 + — —
19 J 19,0 10,5 8,6 8,6 8,0 8,6 8,6 17,6 — —
22 J 21,7 9,0 + + + + + + + +
27 J 26,7 9,0 16,1 16,1 16,1 15,0 + 21,0 — —
32 J 45,6 14,10 30,0 35,0 19,0 22,0 28,0 17,0 16,0 22,0
43 J 21,2 1,6 + + + + + 19,0 + 19,0
39 A 49,9 5,7 + + 42,6 41,8 + EC 41,8 41,8
a All ages and post-HSCT follow-up times represented as years, months; LI Late-Infantile, J Juvenile, A Adult, EC Education completed,— Never achieved ADL, + Currently
performing ADL
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M1 M2 M3 M4 M5 M6 E1 E2 E3 E4 Dress Feed Meal Toilet Hyg. Sch. Work Ind.
A (3) LI 0,8 (No) — — 1,3 1,6 2,0 2,3 2,6 2,9 3,0 5,5 — — — — — — — — 0,1 19,11
A (3sib) LI No HSCT 1,4 1,9 2,0 2,2 2,3 2,10 1,4 1,7 1,7 1,7 — — — — — — — — N/A (4,6)
B (4) J 4,10 (Yes) 3,0 12,0 12,0 12,0 12,0 24,0 3,0 5,0 18,0 + — 13,0 — — — 21,0 26,0 — 1,7 34,11
B (4sib) J No HSCT 4,0 4,0 5,0 5,0 5,0 5,0 4,0 4,0 5,0 5,0 — 4,6 — 4,0 — 9,0 — — N/A (9,3)
C (10) J 5,8 (Yes) 5,0 7,2 7,9 8,0 9,0 + 6,8 8,0 + + 5,10 6,6 — 6,6 7,0 + — — 1,0 24,0
C (10sib) J No HSCT 5,0 5,6 6,8 7,0 7,4 7,10 5,6 6,0 6,8 7,2 5,3 5,10 — 5,10 5,10 9,0 — — N/A (18,0)
D (17) J 7,8 (Yes) 6,0 7,0 9,0 9,7 12,0 13,4 6,0 9,7 12,6 15,0 9,0 9,0 — 6,0 8,0 + — — 0,5 19,4
D (17sib) J 4,3 (No) 13,0 + + + + + 14,0 + + + + + — + + + — — X 15,2
E (27) J 16,1 (Yes) 16,0 16,0 16,0 16,0 16,0 + 16,0 + + + 16,1 16,1 16,1 15,0 + 21,0 — — 3,0 26,6
E (22) J 11,1 (No) + + + + + + + + + + + + + + + + + + 21,6 21,6
Ages expressed as years, months; sib Sibling not in our HSCT cohort, LI Late-Infantile, J Juvenile, Sx Symptoms present at transplant, HSCT Hematopoietic stem cell transplantation, a Age in years, months at entry into
respective level, see Fig. 1 for GMFC-MLD and ELFC-MLD level definitions, b Age at loss of independent performance of common activities of daily living, Dress Dressing oneself, Feed Feeding oneself, Meal Meal
preparation, Toilet Toileting, Hyg Self-hygiene, Sch School participation, Work Work/volunteer participation, Ind Independent living, c Vineland Adaptive Behavior Scales (VABS) composite functional age equivalent score














As expected given their propensity to have a slower nat-
ural history decline, our J-MLD patients showed better
preservation of motor and expressive language function
following HSCT when compared to LI-MLD counterparts .
A relatively large number of long-term J-MLD survivors
(n = 13) were evaluable for gross motor and expressive
language functioning at a median age of 23 years at the
most recent assessment. Of this J-MLD group, 7 patients,
all symptomatic at the time of transplant, demonstrated
motor decline following HSCT similar to that described
by J-MLD natural history cohorts [5, 17]. Interestingly,
relative preservation of expressive language was seen
for these same patients at the same time. In contrast,
other J-MLD patients, particularly those who were pre-
symptomatic or only had mild deficits at transplant-
ation, demonstrated gradual or no loss on the GMFC-
MLD and ELFC-MLD scales.
The relative preservation of skills and increased vari-
ability of response to HSCT in J-MLD may be due to
the greater phenotypic variation within this subtype.
Therefore, when comparing performance on the LEUK-
ONET scales between the transplanted and reported
non-transplanted J-MLD groups, it may be most useful
to assess the age of entry into early levels of motor and
expressive language dysfunction which would represent
more subtle disability. While 2 J-MLD patients in the
cohort continue to show no evidence of motor dysfunc-
tion at last follow-up, 11 have entered into motor levels
1 and 2 (Fig. 1) at mean ages of 139 and 167 months,
respectively. In contrast, the LEUKONET group reported
median entry for untreated J-MLD into the same levels
at 64.5 and 91 months, respectively [20]. Comparison
with the small number of J-MLD patients reported in
the Brazilian natural history study also suggests superior
motor performance for transplanted J-MLD patients in
our cohort [17].
Expressive language function of the transplanted J-
MLD group also appeared better than reports for un-
treated counterparts. While the LEUKONET group
reported 50 % of their untreated J-MLD cohort having
first evidence of language decline (E1-50 %) at approxi-
mately 90 months of age, our surviving transplanted
cohort of 13 reached E1-50 % at age 105 months [22].
Furthermore, LEUKONET data revealed 50 % of the J-
MLD natural history cohort experienced a total loss of
expressive language (E4-50 %) at age 150 months [22].
In contrast, in our transplanted cohort only 4 of 13
evaluable J-MLD patients (31 %) have fully lost expres-
sive language at an average age of 147 months. Import-
antly, the mean age at most recent follow-up for the
remaining 9 transplanted J-MLD patients with func-
tioning level E3 or better is 287 months. Overall, the
aggregate motor and expressive language function over
time of evaluable J-MLD patients in our transplanted
cohort appears to be favorable when compared to pre-
vious natural history reports.
Neuroradiographic and neurophysiologic outcomes
following HSCT for our cohort generally mirror those
reported by others [35, 36]. Lack of access to consistent,
primary source data and images precluded our ability to
provide longitudinal quantitative description. By qualita-
tive assessment, most patients demonstrated relatively
stable brain MRI white matter disease over time. Some
patients, particularly in the LI-MLD group, showed im-
provement following HSCT, though this may have
reflected developmental myelination rather than trans-
plant effect. J-MLD patients were most likely to show
myelin loss following transplant, but the reason for this
is unclear. What is more evident is that the stabilization
of MRI findings did not equate to stabilization of periph-
eral nerve disease. With very few exceptions, NCV scores
followed serially throughout the pre- and post-transplant
course were conspicuous for a frequent decline over time,
even if MRIs performed at the same point in time were
similar or better than previous exams (Fig. 5). These
collective findings appear to support previous reports and
speculations that ARSA secretion by hematopoietically-
derived cells of donor origin may more favorably impact
central nervous demyelination compared to peripheral
nervous system disease [15, 37, 38].
Long-term adaptive behavior functioning and cognitive
outcome data after HSCT for MLD are sparse in the
medical literature. In our cohort, most long-term survi-
vors had adaptive behavior functioning data captured by
the composite VABS score across multiple pre- and
post-transplant time points. An inherent advantage of
this tool is its reliability in assessing function remotely.
Indeed, by parental telephone survey we were able to
evaluate 12 long-term survivors in our cohort for current
adaptive behavior functioning at a median post-HSCT
follow-up of more than 13 years. Although some LI-MLD
and J-MLD patients initially displayed adaptive behavior
functioning trajectories within a normal range, almost all
patients eventually plateaued and then regressed. All eva-
luable A-MLD patients in the cohort were symptomatic at
the time of HSCT and showed relatively stable, although
abnormally low, adaptive behavior functioning over time.
In contrast to adaptive behavior functioning, longitudinal
VIQ appeared to demonstrate less dramatic decline over
time for evaluable patients. This finding perhaps also
supports relative sparing of central nervous system func-
tion, as compared to peripheral nervous system function,
following transplant for MLD.
As parents and clinicians consider the utility of HSCT
for MLD, they may wish to weigh quality-of-life and daily
functioning aspects of patients’ post-transplant courses.
Tables 3 and 4 show intriguing data characterizing these
outcomes. In this study we used the Cornell-Brown Scale,
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as it has been designed for proxy (parent/caregiver) assess-
ment of quality-of-life in patients with dementing disor-
ders. Of 12 evaluable long-term survivors, 11 had positive
(greater than zero) total scores suggesting a favorable
quality-of-life. Furthermore, many J-MLD and A-MLD
patients retained the ability to independently perform a
wide array of ADLs many years after transplant. Although
no robust published data addressing these aspects of
untreated MLD patients exist for comparison, these find-
ings may provide more concrete evidence which parents
might utilize in making the difficult decision to have their
child with MLD undergo transplant. We ultimately asked
parents if they were satisfied with their decision to have
their child undergo HSCT for MLD. All 11 respondents
(100 %) answered affirmatively at a median follow-up of
over 12 years following transplant. Interestingly, over half
of these responding parents had another child with MLD,
many of whom were either not transplanted (due to
advanced disease at diagnosis) or underwent transplant-
ation but died due to treatment-related complications.
Marked variation in MLD phenotypes, even within a
subtype classification, have greatly hampered the ability
to generalize outcomes following treatment. Although
intra-familial disease behavior can also vary, it may be
less likely to do so. As such, sibling cohort comparisons
might allow for optimal assessment of intervention effi-
cacy [8, 12, 39, 40]. Therefore, we described outcome
data for all available sibling pairs in which at least one
sibling underwent transplant in our cohort (Table 5). Of 5
total dyads, 3 consisted of one treated and one untreated
sibling; in all cases, the treated patient has survived their
deceased sibling by a significant margin. Expressive lan-
guage and ADL function were notably superior for all
transplanted patients as well. For one LI-MLD pair (A),
our transplant cohort member experienced more rapid
motor decline compared to her non-transplanted sibling.
The reason for this is unclear but may stem from
transplant-related toxicity as the decline was immediately
following HSCT. It should be noted, however, that this pa-
tient demonstrated prolonged preservation of expressive
language function compared to her untreated sibling and
is still alive nearly 15 years longer than she might presum-
ably be without transplant. For the sibling pairs in which
both were transplanted, the pre-symptomatic siblings con-
tinue to demonstrate significantly greater retention of
function compared to their symptomatic counterparts,
again reflecting the importance of transplant in delaying
disease progression. In one such sibling dyad, J-MLD pair
E, both sisters were transplanted in our cohort. While
both patients survive to date, patient ID22 (pre-symptom-
atic at HSCT) has shown a dramatically superior clinical
course characterized by normal-for-age motor, expressive
language, ADL, and adaptive functioning. Although she
experiences seizures, at age 21 years she is pursuing a
university degree. In contrast, her sister, symptomatic at
transplant, showed relatively significant decline over the
same period. In the other such dyad, J-MLD pair D, the
symptomatic familial proband (ID17) underwent trans-
plant in our cohort, while her brother was transplanted
while pre-symptomatic at another center. He continues to
demonstrate superior function in motor, expressive lan-
guage and ADL performance when compared to his sister.
In summary, these sibling pair data suggest utility in
HSCT for MLD and highlight the dramatic benefit that
HSCT may provide when performed pre-symptomatically
in J-MLD.
While our study provides a relatively robust characterization
of various outcomes following HSCT for MLD, there
are several recognized limitations. First, owing to the
relatively high prevalence of the ARSA pseudodefi-
ciency allele, it is important to acknowledge that low
ARSA activity alone is not sufficient to diagnose MLD.
Exclusion of other rare demyelinating disorders (with
coincidental ARSA pseudodeficiency carriage) is typic-
ally achieved by the demonstration of hyper-excretion
of accumulating substrate (urine sulfatide assessment),
pathognomonic histopathology on nervous tissue bi-
opsy, or/and presence of causative ARSA mutations on
molecular analysis [30]. Very few patients in our cohort
had evaluable histopathologic or ARSA mutation data
for confirmation of MLD diagnosis. All 40 patients
included in our analysis had either primary or second-
ary source documentation of elevated urine sulfatide
excretion to implicate MLD as causative of their low
ARSA activity and personal or family history of leuko-
dystrophy. As well, patients for whom only secondary
source data exists for confirmation of MLD diagnosis
are cautiously included in this analysis.
The span of time encompassed in this cohort, nearly
three decades, carries with it certain inherent analytic
risks and biases. Some data, especially before electronic
medical records were widely available, were not as read-
ily collected or evident in paper charts. Yet all attempts
were made to track down any data through all resources
available. While quantifiable assessment of longitudinal
changes in the neuroradiographic and neurophysiologic
burdens of MLD are ideal, the lack of retrospective
access to consistently obtained, primary source data rele-
gated our analysis to a qualitative one. We were also
limited in terms of longitudinal data by difficulties in
contacting family members of survivors. However, over
half of the families were reached and were willing to par-
ticipate, some of them decades out from their transplant.
Since MLD is a very rare disease and it is even rarer to
present in time to be a candidate for transplant, this par-
ticipation was encouraging and important for analysis of
long-term outcomes. The potential exists for recall bias
in regards to the retrospective assessment of GMFC-
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MLD, ELFC-MLD and ADL skills. Yet we recognize that
the exact timing of when these abilities were lost is less
important than the general trends of skill retention. It
must also be noted that all of these skills gradually dimin-
ish over time rather than abruptly change which can limit
precision. Still, existing natural history data has similarly
relied on retrospective parental assessments [20, 22].
Though our data add to existing evidence suggesting
utility in HSCT for MLD, it is also clear from both this
and previous analyses that transplantation is generally not
expected to fully abrogate disease manifestations. And
though it would be intriguing to formally assess the effects
of graft source, conditioning regimen, age, symptom status
and degree of donor hematopoietic engraftment on func-
tional outcomes following transplant for MLD, the small
number of evaluable patients in our cohort along with
relative homogeneity of outcomes precluded such formal
analysis. Still, the limits of HSCT are particularly evident
in LI-MLD, even when the child is treated prior to clinic-
ally evident disease. Clearly, novel treatment strategies are
needed that could be used independently of transplant-
ation or in association with it. A recent report docu-
mented the utility of genetically corrected autologous
hematopoietic stem cell therapy in a small MLD case
series; larger systematic gene therapy studies are ongoing
[41]. And although broad-population newborn screening
is attractive for the purpose of very early intervention, sev-
eral unique aspects of MLD present significant challenges
to identifying those newborns with true “disease” [42].
Conclusion
In summary, we report outcomes of the largest single-
center cohort of patients who have undergone HSCT for
MLD. Our analysis highlights both the potential benefits,
as well as limitations, of HSCT for MLD across all three
clinical subtypes. While our data strongly suggest efficacy
from early, pre-symptomatic transplant in later-onset
MLD phenotypes, it also suggests objective and perceived
benefits for long-term survivors across all MLD subtypes.
While most patients ultimately experienced neurologic
decline following transplant, HSCT appears to more favor-
ably impact the trajectory of natural progression of cogni-
tive compared to motor dysfunction. Treatment with
HSCT should be carefully considered for patients with
MLD, as investigations into other treatment modalities
aimed at improving outcomes continue [41, 43, 44].
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